First-Degree Familial Risk in Blood Cancer Development
New data suggest that people who have a parent, sibling, or child with blood cancer have a higher likelihood of being diagnosed with a hematologic malignancy themselves. A study by Sud et al published in Blood offers the first evidence that such familial risks exist across the spectrum of hematologic malignancies.
Age of diagnosis; whether the relative is a parent, sibling, or child; and the number of affected first-degree relatives play a defining role in the relative risk of developing certain blood cancers, according to the study.
“This information improves our understanding of the causes of—and potential inherited predisposition to—blood cancers, and should inform the identification and characterization of genetic risk factors for blood cancer, as well as how we best clinically manage patients and their relatives,” said lead study author Amit Sud, MD, PhD, of The Institute of Cancer Research, London. “The results should also encourage conversations among families, clinicians, and patients about familial risk.”
While earlier studies have demonstrated the increased risk of blood cancers in first-degree relatives of affected individuals, this is the largest and most comprehensive population-based evaluation to date.
The present analysis drew from 16 million people in the Swedish Family-Cancer Database, ultimately including 153,115 patients with a confirmed blood cancer and 391,131 first-degree relatives. This allowed researchers to fully characterize familial risk across all blood cancer types.
Study Results
Cases with a familial link represented 4.1% of all blood cancer diagnoses—higher than cancers of the nervous system, kidney, and pancreas, but lower than those of the breast, colorectum, and prostate, which range from 8% to 15%, researchers report. Highest relative risks were seen for certain Hodgkin lymphoma subtypes, lymphoplasmacytic lymphoma, and mantle cell lymphoma. Markedly elevated familial risks were also observed for polycythemia vera, myelodysplasia, and essential thrombocythemia.
For specific blood cancers such as chronic lymphocytic leukemia (CLL), the increase in risk was dependent on the age of the affected relative; whether it is a parent, sibling, or child; and the number of affected first-degree relatives. For example, for non-Hodgkin lymphoma, Hodgkin lymphoma, and CLL, the risk was higher among those who had a sibling with the disease, whereas others blood cancers were more likely to occur if a parent had been diagnosed. Generally, the familial risk was more pronounced when relatives were diagnosed at younger ages. Dr. Sud added that the analysis also has potential implications for the selection of related stem-cell donors used for the treatment of these malignancies.
In addition to its size and long follow-up, another strength of the analysis is its use of registry data, which included almost all blood cancer cases in the Swedish population that had been recorded. Still, researchers said the findings may not be applicable to economically developing countries that tend to have different tumor incidence rates and potentially different environmental and genetic risk factors.
Although there are currently no definitive screening initiatives for blood cancers, a 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia recognized familial disease as an essential component of diagnosing certain subsets of blood cancers and underscores the need to further examine and understand familial risk. Developing definitive screening protocols based on evidence is an emerging area of research.
“We hope these robust data will be used to inform guidelines on genetic testing and screening. Certainly, there are a number of individuals, such as those with a relative diagnosed at a young age and or with more than one affected first-degree relatives, for whom counseling, genetic testing, and surveillance may be appropriate,” concluded Dr. Sud.
Disclosure: For full disclosures of the study authors, visit bloodjournal.org.
The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.
